Get started
Author

Yunah Han

Observed names: Y. Han, Yu Han
Observed institutions: European Organisation for Research and Treatment of Cancer, Vassar College, Mayo Clinic, The University of Texas MD Anderson Cancer Center, Seoul National University, Davidson College, Shandong University, Harbin Medical University, Zhengzhou University, Dalian University, Cangzhou Central Hospital, Third Affiliated Hospital of Harbin Medical University, Novartis (United States), European Organisation for Research and Treatment of Cancer, Takeda (United States), Henan Cancer Hospital, Xijing Hospital, Qilu Hospital of Shandong University, Air Force Medical University
ORCID: 0009-0008-0715-2142
Observed ORCID: 0009-0008-0715-2142
OpenAlex ID: A5101565391
Targeted therapy in esophageal cancer
2016 · Lei Zhang, Jiaojiao Ma, et al. · Expert Review of Gastroenterology & Hepatology · 58
Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival
2015 · Ming-Wen An, Xinxin Dong, et al. · JNCI Journal of the National Cancer Institute · 25
PDF
Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer
2020 · Yoon‐Sim Yap, Joanne Chiu, et al. · Cancer Science · 22
PDF
EPIK-O/ENGOT-OV61: Alpelisib Plus Olaparib vs Cytotoxic Chemotherapy in High-Grade Serous Ovarian Cancer (Phase III Study)
2022 · Panagiotis A Konstantinopoulos, Antonio Gonzalez-Martin, et al. · Future Oncology · 21
352TiP EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2–positive (HER2+) advanced breast cancer (ABC)
2020 · S.A. Hurvitz, S.K.L. Chia, et al. · Annals of Oncology · 12
Apatinib with etoposide capsules as a third- or further-line therapy for extensive-stage small cell lung cancer: an open-label, multicenter, single-arm phase II trial
2021 · Zhen He, Hanqiong Zhou, et al. · Translational Lung Cancer Research · 10
PDF
LBA1 First-line ribociclib + letrozole in postmenopausal Asian women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): A subgroup analysis from MONALEESA-2
2016 · Y.S. Yap, L-M. Tseng, et al. · Annals of Oncology · 9
Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods
2015 · Ming-Wen An, Yu Han, et al. · Journal of Clinical Oncology · 7
PDF
IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer
2025 · Anca Chelariu-Raicu, Thanh Chung Vu, et al. · Cancer Research Communications · 5
Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial
2023 · Jinglei Qu, Xin He, et al. · Frontiers in Oncology · 4
Abstract 4926: Alpelisib in combination with trastuzumab and pertuzumab as maintenance therapy in patients with HER2+, PIK3CA-mutant advanced breast cancer: EPIK-B2 Study Part 1 safety and efficacy results
2023 · Sara A. Hurvitz, François-Clement Bidard, et al. · Cancer Research · 4
Clinical Outcomes Following Simple or Complex Stenting for Coronary Bifurcation Lesions: A Meta-Analysis
2022 · Qun Zhang, Hengshan Huan, et al. · Clinical Medicine Insights Cardiology · 3
Efficacy of Camrelizumab in Advanced Non-Small-Cell Lung Cancer and Prognostic Analysis of Different PET/CT Features
2022 · Jinhai Zou, Chunying Li, et al. · Journal of Oncology · 2
PDF
Short-term efficacy of angiotensin receptor-neprilysin inhibitor treatment in patients with ST-segment elevation myocardial infarction with reduced ejection fraction after primary percutaneous coronary intervention: a propensity score matching study
2022 · Qun Zhang, Bao Qiao, et al. · BMC Cardiovascular Disorders · 1
PDF
EPV279/#351 EPIK-O/ENGOT-OV61: a phase 3, randomized study of alpelisib + olaparib in patients with no germline brca mutation detected, platinum-resistant or -refractory, high-grade serous ovarian cancer
2021 · P. Konstantinopoulos, A. González-Martín, et al. · International Journal of Gynecological Cancer · 1
PDF
Investigation of the mechanisms by which norcantharidin enhances oxaliplatin action in colorectal cancer
2025 · Yu Han, Da-Zhi Gao, et al. · Asian Journal of Surgery
Supplementary Table 2 from IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer
2025 · Anca Chelariu-Raicu, Thanh Chung Vu, et al.
Supplementary Movie 1 from IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer
2025 · Anca Chelariu-Raicu, Thanh Chung Vu, et al.
Supplementary Figures from IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer
2025 · Anca Chelariu-Raicu, Thanh Chung Vu, et al.
PDF
Supplementary Movie 2 from IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer
2025 · Anca Chelariu-Raicu, Thanh Chung Vu, et al.
Supplementary Table 1 from IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer
2025 · Anca Chelariu-Raicu, Thanh Chung Vu, et al.
Supplementary Table 3 from IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer
2025 · Anca Chelariu-Raicu, Thanh Chung Vu, et al.
Supplementary Table 1 from IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer
2025 · Anca Chelariu-Raicu, Thanh Chung Vu, et al.
Supplementary Movie 2 from IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer
2025 · Anca Chelariu-Raicu, Thanh Chung Vu, et al.
Figure 4 from IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer
2025 · Anca Chelariu-Raicu, Thanh Chung Vu, et al.
Works count: 39
Citation count: 184
H-index: 7
I10-index: 6
Year
Topic
Type